Hitoshi Yoshiji

Summary

Affiliation: Nara Medical University
Country: Japan

Publications

  1. ncbi Possible involvement of angiogenesis in chronic liver diseases: interaction among Renin-Angiotensin-aldosterone system, insulin resistance and oxidative stress
    K Kaji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Curr Med Chem 19:1889-98. 2012
  2. ncbi Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Curr Med Chem 14:2749-54. 2007
  3. ncbi Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8521, Japan
    Gut 54:1768-75. 2005
  4. ncbi Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, School of Medicine, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 14:213-8. 2005
  5. ncbi Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Hepatol 42:687-93. 2005
  6. ncbi Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development
    Hitoshi Yoshiji
    The Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 13:853-7. 2005
  7. ncbi Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 13:491-5. 2005
  8. ncbi Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Japan
    Liver Int 25:153-61. 2005
  9. ncbi Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8521, Japan
    Am J Physiol Gastrointest Liver Physiol 288:G907-13. 2005
  10. ncbi Impact of renin-angiotensin system in hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Shijo cho 840, Kashikan, Nara 634 8522, Japan
    Curr Cancer Drug Targets 11:431-41. 2011

Collaborators

Detail Information

Publications92

  1. ncbi Possible involvement of angiogenesis in chronic liver diseases: interaction among Renin-Angiotensin-aldosterone system, insulin resistance and oxidative stress
    K Kaji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Curr Med Chem 19:1889-98. 2012
    ..Collectively, the anti-angiogenic treatment targeting RAAS, IR, ROS with clinically available agents may become a new therapeutic strategy against the progression of chronic liver diseases...
  2. ncbi Renin-angiotensin system inhibitors as therapeutic alternatives in the treatment of chronic liver diseases
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Curr Med Chem 14:2749-54. 2007
    ..Since RAS inhibitors are widely used in the clinical practice without serious side effects, they may represent a potential new therapeutic strategy against the progression of chronic liver diseases...
  3. ncbi Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8521, Japan
    Gut 54:1768-75. 2005
    ..However, few studies have focused on the direct interaction of these factors on in vivo tumour development and angiogenesis...
  4. ncbi Combination of copper-chelating agent, trientine, and methotrexate attenuates colorectal carcinoma development and angiogenesis in mice
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, School of Medicine, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 14:213-8. 2005
    ..Because both agents are widely used in clinical practice, the combination regimen may represent a potential new strategy for CRC therapy in the future...
  5. ncbi Combination of vitamin K2 and the angiotensin-converting enzyme inhibitor, perindopril, attenuates the liver enzyme-altered preneoplastic lesions in rats via angiogenesis suppression
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Hepatol 42:687-93. 2005
    ....
  6. ncbi Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development
    Hitoshi Yoshiji
    The Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 13:853-7. 2005
    ..These results suggested that both VEGFR-1 and VEGFR-2 play important roles, and lie in the different signaling cascades by which VEGF augments HCC development and angiogenesis...
  7. ncbi Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 13:491-5. 2005
    ..These results suggested that the combination treatment with IFN and PE may be an effective new strategy for chemoprevention against HCC...
  8. ncbi Combination of interferon-beta and angiotensin-converting enzyme inhibitor, perindopril, attenuates the murine liver fibrosis development
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Japan
    Liver Int 25:153-61. 2005
    ..The combination treatment of the clinically used PE and IFN may provide a new strategy for anti-liver fibrosis therapy...
  9. ncbi Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8521, Japan
    Am J Physiol Gastrointest Liver Physiol 288:G907-13. 2005
    ..Because STI-571 is widely used in clinical practice, it may provide an effective new strategy for antifibrosis therapy...
  10. ncbi Impact of renin-angiotensin system in hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Shijo cho 840, Kashikan, Nara 634 8522, Japan
    Curr Cancer Drug Targets 11:431-41. 2011
    ....
  11. ncbi Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Curr Cancer Drug Targets 4:555-67. 2004
    ..Since ACE-Is are already in widespread clinical case without any serious adverse effects, they may represent a potential new strategy for cancer therapy and chemoprevention...
  12. ncbi Salvage living donor liver transplantation after percutaneous transluminal angioplasty for recurrent Budd-Chiari syndrome: a case report
    Yusaku Shirai
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    J Med Case Reports 5:124. 2011
    ..abstract:..
  13. ncbi Suppression of renin-angiotensin system attenuates hepatocarcinogenesis via angiogenesis inhibition in rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Anticancer Res 25:3335-40. 2005
    ..These results suggested that RAS plays an important role in hepatocarcinogenesis, at least partly through VEGF-mediated angiogenesis...
  14. ncbi The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure
    Tadashi Namisaki
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Angiogenes Res 2:16. 2010
    ..In conclusion, these results indicated that R2 is a major regulator of the salvage effect of VEGF on the maintenance of SEC architecture and the anti-apoptotic effects against chemically-induced murine AHF...
  15. ncbi Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    World J Gastroenterol 13:3259-61. 2007
    ..Since both VK and ACE-I are widely used without serious side effects, this combined regimen may become a new strategy for chemoprevention against HCC...
  16. ncbi Blockade of renin-angiotensin system in antifibrotic therapy
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    J Gastroenterol Hepatol 22:S93-5. 2007
    ..Because both ACE-I and ARB are widely used in clinical practice without serious side-effects, these drugs in combination with IFN may provide a new strategy for antifibrosis therapy...
  17. ncbi Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report
    Tsuyoshi Mashitani
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Cases J 2:18. 2009
    ..abstract:..
  18. ncbi Branched-chain amino acids suppress insulin-resistance-based hepatocarcinogenesis in obese diabetic rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    J Gastroenterol 44:483-91. 2009
    ..However, the possible mechanism is still obscure. The aim of the present study was to examine the effect of BCAAs, especially in conjunction with angiogenesis, on hepatocarcinogenesis under the condition of IR...
  19. ncbi Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    BMC Res Notes 2:70. 2009
    ..CONCLUSION: Since losartan is widely used without serious side effects in the clinical practice, this agent may be an effective new therapeutic strategy against NASH...
  20. ncbi Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Hepatol 51:315-21. 2009
    ....
  21. ncbi Interferon augments the anti-fibrotic activity of an angiotensin-converting enzyme inhibitor in patients with refractory chronic hepatitis C
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    World J Gastroenterol 12:6786-91. 2006
    ..To evaluate the effect of combination treatment with the interferon (IFN) and angiotensin-converting enzyme inhibitor (ACE-I) on several fibrotic indices in patients with refractory chronic hepatitis C (CHC)...
  22. ncbi Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634 8522, Japan
    Int J Mol Med 17:899-904. 2006
    ..Since both agents are widely used in clinical practice, this combination therapy may provide a new strategy against liver fibrosis in the future...
  23. ncbi Attenuation of insulin-resistance-based hepatocarcinogenesis and angiogenesis by combined treatment with branched-chain amino acids and angiotensin-converting enzyme inhibitor in obese diabetic rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Gastroenterol 45:443-50. 2010
    ....
  24. ncbi Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Japan
    Oncol Rep 15:155-9. 2006
    ..Since both VK and ACE-I are widely used in clinical practice without serious side effects, this combination therapy may be an effective new therapeutic strategy against hepatocarcinogenesis and HCC growth in the future...
  25. ncbi Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, 634 8522 Nara, Japan
    J Hepatol 41:97-103. 2004
    ..The aim of this study was to examine the role of VEGFR-1 in VEGF-mediated HCC development and angiogenesis as compared to that of VEGFR-2...
  26. ncbi Halting the interaction between vascular endothelial growth factor and its receptors attenuates liver carcinogenesis in mice
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Hepatology 39:1517-24. 2004
    ..In conclusion, these results suggest that VEGF and receptor interaction plays an important role in hepatocarcinogenesis and in spontaneous lung metastasis from HCC...
  27. ncbi Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Int J Mol Med 28:81-8. 2011
    ..These results indicate that the cocktail combination treatment of clinically used IFN, Rib and ARB may provide a new strategy for anti-liver fibrosis therapy...
  28. ncbi Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Japan
    Hepatology 36:850-60. 2002
    ..In conclusion, TIMP-1 significantly attenuated spontaneous resolution of liver fibrosis by the combination of a net reduction of the MMP activity and suppression of apoptosis in HSC...
  29. ncbi Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: a randomized control trial
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634 8522, Japan
    Oncol Rep 26:1547-53. 2011
    ..Moreover, sVEGFR2 may become a useful clinical predictive marker of this combination treatment...
  30. ncbi Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    J Hepatol 37:22-30. 2002
    ..The aim of the present study was to examine the effect of RAS inhibition on the liver enzyme-altered preneoplastic lesions and fibrosis development...
  31. ncbi Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, 840 Shijo chu, Kashihara 634 8522, Japan
    Int J Oncol 20:1227-31. 2002
    ..In vitro study showed that perindoprilat, which is an active form of PE, inhibited VEGF-induced endothelial cell migration. These results suggested that RAS played an important role in VEGF-mediated tumor development and angiogenesis...
  32. ncbi Perindopril: possible use in cancer therapy
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Anticancer Drugs 13:221-8. 2002
    ..Since perindopril is already in widespread clinical use without serious side effects, it may represent a potential new strategy for anticancer therapy...
  33. ncbi Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Hepatology 34:745-50. 2001
    ..Because both CA and PE are widely used in clinical practice without serious side effects, these drugs may provide an effective new strategy for anti-liver fibrosis therapy...
  34. ncbi Extracellular matrix remodeling may predominate over hepatocyte injury in hepatocellular carcinoma development
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    Oncol Rep 10:957-62. 2003
    ..These results suggested that the ECM remodeling plays a more important role than the persistent hepatocyte injury in the liver enzyme-altered preneoplastic lesion development in the rat...
  35. ncbi The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, 840 Shijo Cho, Kashihara Nara 634 8522, Japan
    Clin Cancer Res 7:1073-8. 2001
    ..Because perindopril is widely used in clinical practice, it may represent an effective new strategy for anticancer therapy...
  36. ncbi The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara 634 8522, Japan
    Hepatology 33:841-7. 2001
    ..These results suggest that KDR/Flk-1 is a major regulator of malignant hepatic ascites formation, and that in addition to VEGF-A, VEGF-C may also be involved in the malignant ascites formation via KDR/ Flk-1 activation...
  37. ncbi The copper-chelating agent, trientine, attenuates liver enzyme-altered preneoplastic lesions in rats by angiogenesis suppression
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara 634 8522, Japan
    Oncol Rep 10:1369-73. 2003
    ....
  38. ncbi Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Gut 52:1347-54. 2003
    ..It has been shown that expression of the potent angiogenic factor, vascular endothelial growth factor (VEGF), and its receptors, flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2), increased during the development of liver fibrosis...
  39. ncbi Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Hepatology 32:1248-54. 2000
    ..These results suggest that TIMP-1 does not by itself result in liver fibrosis, but strongly promotes liver fibrosis development...
  40. ncbi KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Hepatology 30:1179-86. 1999
    ..These results suggest that KDR/Flk-1 is a major regulator of VEGF-mediated HCC development and angiogenesis not only at the initial stage, but also after the tumor has fully developed...
  41. ncbi Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Japan
    Cancer Res 59:4413-8. 1999
    ..These results suggest that PKC-beta lies on the signal transduction pathway by which VEGF augments development and angiogenesis not only at the initial stage but also after the tumor is fully established...
  42. ncbi Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells
    H Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Hepatology 28:1489-96. 1998
    ..These results suggested that VEGF plays a critical role in the development of HCC in cooperation with EC..
  43. ncbi Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara Nara, Japan
    Hepatology 35:834-42. 2002
    ..In conclusion, these results suggest that bFGF synergistically augments VEGF-mediated HCC development and angiogenesis at least partly by induction of VEGF through KDR/Flk-1...
  44. ncbi Combination of branched-chain amino acid and angiotensin-converting enzyme inhibitor improves liver fibrosis progression in patients with cirrhosis
    Hitoshi Yoshiji
    The Third Department of Internal Medicine, Nara Medical University, Nara 634 8522, Japan
    Mol Med Report 5:539-44. 2012
    ....
  45. ncbi Vitamins K2, K3 and K5 exert in vivo antitumor effects on hepatocellular carcinoma by regulating the expression of G1 phase-related cell cycle molecules
    Shigeki Kuriyama
    Third Department of Internal Medicine, Kagawa University School of Medicine, Kita gun, Kagawa 761 0793, Japan
    Int J Oncol 27:505-11. 2005
    ..These results also indicate that vitamins K2, K3 and K5 may be useful agents for the treatment of patients with HCC...
  46. ncbi Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor
    Hitoshi Yoshiji
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Tumour Biol 23:348-56. 2002
    ..Since ACE inhibitor is used widely in clinical practice without serious side effects, it may provide an alternative new strategy for the treatment of liver fibrosis and HCC...
  47. ncbi Impact of insulin resistance on the progression of chronic liver diseases
    Kosuke Kaji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Int J Mol Med 22:801-8. 2008
    ....
  48. ncbi Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities
    Koji Yanase
    Third Department of Internal Medicine, Nara Medical University, Nara 634 8522, Japan
    Oncol Rep 17:441-6. 2007
    ..Since both 5-FU and ACE-I are widely used in clinical practice, this combination therapy may be an effective new therapeutic strategy against HCC in the future...
  49. ncbi Repetitive and safe transgene expression in rat liver is achievable by adenoviral infusion into the common bile duct
    Shigeki Kuriyama
    Third Department of Internal Medicine, Kagawa University School of Medicine, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Int J Mol Med 16:503-8. 2005
    ....
  50. ncbi Relationship between the proliferative capability of hepatocytes and the intrahepatic expression of hepatocyte growth factor and c-Met in the course of cirrhosis development in rats
    Hideyuki Inoue
    Third Department of Internal Medicine, Kagawa University School of Medicine, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Int J Mol Med 17:857-64. 2006
    ....
  51. ncbi Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis
    Ryuichi Noguchi
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Clin Cancer Res 9:6038-45. 2003
    ..Because both agents are widely used in clinical practice, this combination regimen may represent a potential new strategy for HCC therapy in the future...
  52. ncbi Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats
    Kosuke Kaji
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan
    Am J Physiol Gastrointest Liver Physiol 300:G1094-104. 2011
    ..Since both agents are widely used in clinical practice, this combination therapy may represent a potential new strategy against NASH in the near future...
  53. ncbi In vitro and in vivo antitumor effects of vitamin K5 on hepatocellular carcinoma
    Misuzu Hitomi
    Third Department of Internal Medicine, Kagawa University School of Medicine, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
    Int J Oncol 26:1337-44. 2005
    ..The results demonstrated here indicate that vitamin K5 may be a useful agent for the treatment of patients with HCC...
  54. ncbi Proliferative capability of hepatocytes and expression of G1-related cell cycle molecules in the development of liver cirrhosis in rats
    Fumi Funakoshi
    Third Department of Internal Medicine, Kagawa University School of Medicine, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
    Int J Mol Med 13:779-87. 2004
    ....
  55. ncbi Safe and efficient transgene expression in rat hepatocytes induced by adenoviral administration into the biliary tract
    Shigeki Kuriyama
    Third Department of Internal Medicine, Kagawa University School of Medicine, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Oncol Rep 13:825-30. 2005
    ....
  56. ncbi Enhanced expression of adaptor molecule p46 Shc in nuclei of hepatocellular carcinoma cells: study of LEC rats
    Shuhei Yoshida
    Third Department of Internal Medicine, Kagawa University School of Medicine, 1750 1 Ikenobe, Kita gun, Kagawa 761 0793, Japan
    Int J Oncol 25:1089-96. 2004
    ....
  57. ncbi Tissue inhibitor of metalloproteinases-1 (TIMP-1) inhibits tumor growth and angiogenesis in the TIMP-1 transgenic mouse model
    Yasuhide Ikenaka
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Int J Cancer 105:340-6. 2003
    ..These results suggested that the ectopically overexpressed TIMP-1 inhibited the tumor growth by angiogenesis suppression...
  58. ncbi Leptin-mediated neovascularization is a prerequisite for progression of nonalcoholic steatohepatitis in rats
    Mitsuteru Kitade
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Hepatology 44:983-91. 2006
    ..In conclusion, these results suggest that leptin-mediated neovascularization coordinated with VEGF plays an important role in the development of liver fibrosis and hepatocarcinogenesis in NASH...
  59. ncbi Synergistic inhibitory effect of gemcitabine and angiotensin type-1 receptor blocker, losartan, on murine pancreatic tumor growth via anti-angiogenic activities
    Ryuichi Noguchi
    Third Department of Internal Medicine, Nara Medical University, Nara 634 8522, Japan
    Oncol Rep 22:355-60. 2009
    ..Since both agents are widely used in the clinical practice, the combination regimen of GEM and Lo may represent a potential new therapeutic strategy for pancreatic cancer in the future...
  60. ncbi Potential role of ADAMTS13 in the progression of alcoholic hepatitis
    Masahito Uemura
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, 634 8522, Japan
    Curr Drug Abuse Rev 1:188-96. 2008
    ..The determination of ADAMTS13:AC and its substrate will give us new insights into the pathophysiology of acute alcoholic liver injury and help to elucidate additional therapeutic strategies for this disease...
  61. ncbi Selective aldosterone blocker ameliorates the progression of non-alcoholic steatohepatitis in rats
    Ryuichi Noguchi
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Int J Mol Med 26:407-13. 2010
    ..These results indicated that Ald plays a pivotal role in the progression of NASH. Considering that SAB is already widely used in clinical practice, this drug could represent a potential new strategy against NASH in the future...
  62. ncbi Immunotherapy for nonalcoholic steatohepatitis using the multiple cytokine production modulator Y-40138
    Tatsuhiro Tsujimoto
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    World J Gastroenterol 15:5533-40. 2009
    ..To investigate the possible use of the multiple cytokine production modulator, Y-40138, as a novel immunotherapy in the rat nonalcoholic steatohepatitis (NASH) model...
  63. ncbi Antitumor effects of vitamins K1, K2 and K3 on hepatocellular carcinoma in vitro and in vivo
    Misuzu Hitomi
    Third Department of Internal Medicine, Kagawa University School of Medicine, Kagawa 761-0793, Japan
    Int J Oncol 26:713-20. 2005
    ..The results indicate that vitamins K2 and K3 may be useful agents for the treatment of patients with HCC...
  64. ncbi Different tumoricidal effects of interferon subclasses and p53 status on hepatocellular carcinoma development and neovascularization
    Ryuichi Noguchi
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Int J Oncol 32:193-9. 2008
    ..A cautious approach may be also required in the clinical practice since even in a same IFN subclass (class-I), IFN-alpha and IFN-beta exert tumoricidal effects of different magnitudes on HCC...
  65. ncbi Potential role of enhanced cytokinemia and plasma inhibitor on the decreased activity of plasma ADAMTS13 in patients with alcoholic hepatitis: relationship to endotoxemia
    Masatoshi Ishikawa
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Alcohol Clin Exp Res 34:S25-33. 2010
    ..The aim of this study was to explore the potential mechanism to reduce the activity of plasma ADAMTS13...
  66. ncbi Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver
    Tsutomu Masaki
    Third Department of Internal Medicine, Kagawa Medical University, Miki-cho, Kita-gun, Kagawa 761-0793, Japan
    Int J Oncol 26:661-71. 2005
    ....
  67. ncbi Innate immune reactivity of the liver in rats fed a choline-deficient L-amino-acid-defined diet
    Hideto Kawaratani
    Third Department of Internal Medicine, Nara Medical University, 840 Shijo Cho, Kashihara, Nara 634 8522, Japan
    World J Gastroenterol 14:6655-61. 2008
    ..To investigate the innate immune reactivity of tumor necrosis factor-alpha (TNF-alpha), Toll-like receptor 4 (TLR4), and CD14 in the liver of non-alcoholic steatohepatitis (NASH) model rats...
  68. ncbi Rapid detection of spontaneous bacterial peritonitis by granulocyte elastase latex immunoassay and reagent strip
    Masaharu Yamazaki
    Central Clinical Laboratory, Nara Medical University Hospital, Kashihara 634 8522, Japan
    Rinsho Byori 59:549-58. 2011
    ..9%, 90.9%, 76.5%, and 97.6%, respectively. These results indicate that GE-LIA and GE reagent strips are rapid and sensitive and can aid diagnosis of SBP...
  69. ncbi Identification of p46 Shc expressed in the nuclei of hepatocytes with high proliferating activity: Study of regenerating rat liver
    Jin Yuji
    Third Department of Internal Medicine, Kagawa University School of Medicine, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Int J Mol Med 13:721-8. 2004
    ..Therefore, it is suggested that p46 Shc expressed in hepatocellular nuclei may be a useful marker for detecting hepatocytes with high proliferative activity...
  70. ncbi Plasma ADAMTS13 activity parallels the APACHE II score, reflecting an early prognostic indicator for patients with severe acute pancreatitis
    Chie Morioka
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Scand J Gastroenterol 43:1387-96. 2008
    ..The purpose of the study was to investigate the potential role of ADAMTS13:AC in the severity of SAP...
  71. ncbi Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis
    Masahito Uemura
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Thromb Haemost 99:1019-29. 2008
    ..An imbalance between the decreased ADAMTS13:AC and its increased substrate may reflect the predisposing state for platelet thrombi formation in patients with advanced LC...
  72. ncbi Cyclins and cyclin-dependent kinases: comparative study of hepatocellular carcinoma versus cirrhosis
    Tsutomu Masaki
    Third Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan
    Hepatology 37:534-43. 2003
    ..Cyclin D1, Cdk4, and cyclin E activation may be closely related to the histopathologic grade and progression of HCC...
  73. ncbi Function of the vascular endothelial growth factor receptors Flt-1 and Flk-1/KDR in the alloimmune response in vivo
    Masayuki Sho
    Department of Surgery, Nara Medical University, Nara, Japan
    Transplantation 80:717-22. 2005
    ..VEGF binds two major VEGF receptors: VEGFR-1 (flt-1) and VEGFR-2 (flk-1/KDR). Here, we wished to investigate the expression and function of VEGF receptors in the process of acute allograft rejection in vivo...
  74. ncbi Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats
    Tadashi Namisaki
    Third Department of Internal Medicine, Nara Medical University, School of Medicine, Shijo-cho 840, Kashihara, Nara 634-8522, Japan
    J Hepatol 44:568-75. 2006
    ..CONCLUSIONS: VEGF treatment significantly reduced the mortality rate of ALI in the rat, and it may provide a new therapeutic strategy for ALI...
  75. ncbi Decreased activity of plasma ADAMTS13 may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis
    Masahito Uemura
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan
    Alcohol Clin Exp Res 29:264S-71S. 2005
    ..The aim of this study was to explore the potential role of ADAMTS13 on the development of liver disturbance and multiorgan failure in AH...
  76. ncbi DNA cytosine methylation profile in various cancer-related genes is altered in cultured rat hepatocyte cell lines as compared with primary hepatocytes
    Kiyoshi Asada
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara 634 8521, Japan
    Oncol Rep 15:1241-8. 2006
    ..This study suggests that a cautious approach is required when cell lines are utilized to study methylation-related carcinogenic, metastatic or tumoricidal mechanisms...
  77. ncbi Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis
    Tomomi Matsuyama
    Third Department of Internal Medicine, Nara Medical University, Kashihara, Nara, Japan
    Alcohol Clin Exp Res 31:S27-35. 2007
    ..We investigated the relationship of ADAMTS13 and von Willebrand factor antigen (VWF:Ag) with the clinical features of AH and SAH...
  78. ncbi Crosstalk between angiogenesis, cytokeratin-18, and insulin resistance in the progression of non-alcoholic steatohepatitis
    Mitsuteru Kitade
    Third Department of Internal Medicine, Nara Medical University, Shijo cho 840, Kashihara, Nara 634 8522, Japan
    World J Gastroenterol 15:5193-9. 2009
    ..To elucidate the possible crosstalk between angiogenesis, cytokeratin-18 (CK-18), and insulin resistance (IR) especially in patients with non-alcoholic steatohepatitis (NASH)...
  79. ncbi Enhancing and suppressing effects of dexamethasone on transgene expression in vitro
    Manabu Akahane
    Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara 634-8522, Japan
    Int J Mol Med 10:107-12. 2002
    ..These results indicate that dexamethasone may play an important role for achieving successful gene therapy. Furthermore, these observations may also have important implications for future clinical applications of gene therapy...
  80. ncbi Adenovirus-mediated gene transfer into rat livers: comparative study of retrograde intrabiliary and antegrade intraportal administration
    Shigeki Kuriyama
    Third Department of Internal Medicine, Kagawa University School of Medicine, Kagawa 761 0793, Japan
    Oncol Rep 13:69-74. 2005
    ....
  81. ncbi Identification of c-Yes expression in the nuclei of hepatocellular carcinoma cells: involvement in the early stages of hepatocarcinogenesis
    Takako Nonomura
    Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Int J Oncol 30:105-11. 2007
    ..In conclusion, nuclear c-Yes expression was found in cancer cells at the early stages of hepatocarcinogenesis, suggesting that nucleus-located c-Yes may be a useful marker to detect early-stage HCC...
  82. ncbi Crosstalk between high-molecular-weight adiponectin and T-cadherin during liver fibrosis development in rats
    Kiyoshi Asada
    Third Department of Internal Medicine, Nara Medical University, Nara, Japan
    Int J Mol Med 20:725-9. 2007
    ..Collectively, since the specific ligand and receptor were augmented together, crosstalk between HMW adiponectin and T-cadherin may play an important role during liver fibrosis development in rats...
  83. ncbi Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1
    Mariana S De Lorenzo
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, R Saenz Pena 180, Bernal B1876BXD, Buenos Aires, Argentina
    In Vivo 17:45-50. 2003
    ..These results support the notion that TIMP-1 displays paradoxical effects on tumor progression and suggest that circulating TIMP-1 is efficient in suppressing lung colonization of melanoma cells...
  84. ncbi Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice
    Masaharu Yamazaki
    Laboratory of Cellular Carcinogenesis and Tumor Promotion, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Carcinogenesis 25:1735-46. 2004
    ..The findings of this study show that circulating TIMP-1, but not mammary-derived TIMP-1, has growth suppressive effects on DMBA and MT-induced mammary carcinomas...
  85. ncbi Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma
    Asahiro Morishita
    Third Department of Internal Medicine, Kagawa Medical University, Kagawa, Japan
    Hepatology 40:677-86. 2004
    ..In conclusion, the loss of p18INK4C expression may play a role in the differentiation and development of HCC through the up-regulation of Cdk4 activity...
  86. ncbi Combined effect of an ACE inhibitor, perindopril, and interferon on liver fibrosis markers in patients with chronic hepatitis C
    Hitoshi Yoshiji
    J Gastroenterol 40:215-6. 2005
  87. ncbi Vitamins K2, K3 and K5 exert antitumor effects on established colorectal cancer in mice by inducing apoptotic death of tumor cells
    Mutsumi Ogawa
    Department of Gastroenterology and Neurology, Kagawa University School of Medicine, Kita gun, Kagawa 761 0793, Japan
    Int J Oncol 31:323-31. 2007
    ....
  88. ncbi Desmopressin reduces melanoma lung metastasis in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1
    Giselle V Ripoll
    Laboratory of Molecular Oncology, Department of Science and Technology, Quilmes National University, Bernal, Buenos Aires, Argentina
    In Vivo 20:881-5. 2006
    ..Our data indicate that DDAVP therapy may impair successful implantation of circulating melanoma cells and suggest that high levels of circulating TIMP-1 display a cooperative role in the antitumor activity of the compound...
  89. ncbi Sequential assessment of the intrahepatic expression of epidermal growth factor and transforming growth factor-beta1 in hepatofibrogenesis of a rat cirrhosis model
    Shigeki Kuriyama
    Department of Gastroenterology and Neurology, Kagawa University School of Medicine, 1750 1 Ikenobe, Miki cho, Kita gun, Kagawa 761 0793, Japan
    Int J Mol Med 19:317-24. 2007
    ....
  90. ncbi Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alpha-2b and ribavirin for chronic hepatitis C
    Mariko Nishiofuku
    Department of Gastroenterology, Ishinkai Yao General Hospital, Yao
    Intern Med 45:483-4. 2006
  91. ncbi Activation of c-Yes in hepatocellular carcinoma: a preliminary study
    Han Feng
    World J Gastroenterol 12:5743-5. 2006
  92. ncbi Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts
    Steven R Harris
    Tumor Biology and Carcinogenesis Section, Laboratory of Cellular Carcinogenesis and Tumor Promotion, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Cancer Lett 179:95-101. 2002
    ..These findings indicate that VEGF contributes to tumor growth through inhibition of apoptosis and increased NOS activity, which may be critical during pre-vascular stages of tumor development...